Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Celularity Inc. CELU

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$26.6M
▼ 51.0% YoY
$-91.7M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

We have a 147,215 square foot purpose-built facility located in Florham Park, New Jersey, which includes a cGMP-ready manufacturing center, along with dedicated research and office spaces and space for shared services. As of December 31, 2025, we had 115 full-time employees and 1 non-employee leased worker, most of whom are located at our Florham Park facility. We acquired our biobanking business in May 2017 from HLI, which HLI operated as LifebankUSA, along with the degenerative disease products Biovance and Interfyl, and in October 2018, we acquired CariCord Inc., or CariCord, a family cord blood bank. In August 2025, we sold certain intellectual property assets to Celeniv Pte. Ltd. (“Celeniv”) and retained rights to such assets pursuant to a license agreement.

Written from the business description in Celularity Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 30 April 2026. Every sentence was checked against that document before publication.

Growth

USD 26.6M
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 26.6 · Net income -91.7
20M40M-100M-200M
201920222025
Compound annual growth
+13.9%
+13.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +13.2% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−345 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -230.9% · Net -345.4%
-500%-1000%
201920222025
ROE
FY2024 · ROE -232.5%
-100%-200%
201920222025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: -116%.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -6.6
-100M-200M
201920222025
Net buybacks $ Dividends $
FY2020 · Dividends · · Net buybacks 118000.0
50000100000
2020

Total assetsUSD 107.3M
EquityUSD -38.1M
CashUSD 6.2M
Gross debtUSD 33.8M
Net debtUSD 27.6M
Current ratio0.15×

Equity was zero or negative — liabilities equaled or exceeded assets. No ratio is shown.

The 7-year record

7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
CELU, 7-year financial record
Metric 2025202420232022202120202019
Revenue $B0.00.10.00.00.00.0◌
Operating income $B−0.1−0.0−0.2−0.0−0.1−0.2−0.0
EBITDA $B−0.1−0.0−0.2−0.0−0.1−0.1◌
Income tax $B0.0◌0.00.00.0−0.00.0
Net income $B−0.1−0.1−0.20.0−0.1−0.20.0
Free cash flow $B◌−0.0−0.0−0.1−0.1−0.1◌
EPS, diluted $−3.59−2.64−11.020.95−1.49−11.310.10
Dividend / sh $◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————
ROE %—−232.5−163.79.5———
Shares out B0.030.020.020.150.120.020.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 1 failure · 4 divergences in 32 reconciliationsAUDITED

Reconciled in 2 of the 7 fiscal years we could check. 4 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 24 checks were skipped: the balance sheet is not tagged before 2019. 13 checks were skipped: revenue is not tagged before 2020. 12 checks were skipped: EPS is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency1 failure4 divergent
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2018

Share this section

Download image